MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine

Core Insights - Moderna has submitted regulatory filings for its seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia, targeting adults aged 50 and above, with plans to commercialize by next year [1][7] - The submissions are supported by late-stage study data indicating that mRNA-1010 generates immune responses comparable to existing flu vaccines from GSK and Sanofi [2][7] - Following the announcement, Moderna's stock rose over 4%, reflecting investor optimism regarding the potential product launch [3] Regulatory and Development Updates - The recent filings may also facilitate a future resubmission of Moderna's investigational COVID-19 and influenza combination vaccine, mRNA-1083, which had previously been withdrawn due to requests for additional efficacy data [4][7] - Moderna has faced challenges, including a 32% decline in stock over the past year, contrasting with a 15% growth in the industry [5][9] - The company has experienced setbacks, including the termination of a $766 million contract for a bird flu vaccine and the failure of its CMV vaccine in a late-stage study [9][10] Market Sentiment - The latest developments are seen as part of Moderna's strategy to improve negative market sentiment surrounding its stock [8]